The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
ApexOnco Front Page
Recent articles
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
On a wing and a prayer Leap heads for phase 3.
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
Opdivo and Yervoy succeed again, but the US path remains unclear.
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
The company might need something better to replace its ageing blockbuster.
Poor efficacy clouds prospects for the company's "improved" Yervoy.